OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in InflaRx (NASDAQ:IFRX) by 21.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 625,589 shares of the company’s stock after selling 172,287 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.06% of InflaRx worth $1,545,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Two Sigma Securities LLC bought a new stake in InflaRx during the fourth quarter valued at about $28,000. Walleye Capital LLC purchased a new position in shares of InflaRx during the 4th quarter valued at about $51,000. Cubist Systematic Strategies LLC bought a new position in shares of InflaRx during the 4th quarter valued at approximately $55,000. Geode Capital Management LLC grew its stake in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares in the last quarter. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IFRX has been the topic of several analyst reports. Guggenheim lifted their price target on shares of InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of InflaRx in a research report on Friday, March 21st. Cantor Fitzgerald initiated coverage on shares of InflaRx in a research note on Tuesday, April 29th. They set an “overweight” rating and a $10.00 target price on the stock. Finally, Oppenheimer initiated coverage on shares of InflaRx in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 target price for the company.

InflaRx Trading Up 7.2%

NASDAQ IFRX opened at $1.79 on Wednesday. InflaRx has a 12 month low of $0.82 and a 12 month high of $2.82. The stock has a market cap of $120.17 million, a PE ratio of -1.66 and a beta of 1.57. The stock’s 50 day moving average is $1.25 and its 200 day moving average is $1.83.

InflaRx (NASDAQ:IFRX) last released its earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.